Search
Sloan Kettering Institute scientists report new findings about a gene that helps regulate DNA methylation.
For the first time, researchers have found an association between the makeup of the microorganisms in the body before a bone marrow transplant and a patient’s survival afterward.
New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.
A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email [email protected].
Breast pathologist Edi Brogi explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease.
Meet Emily Herzlin, who teaches mindfulness and meditation at Memorial Sloan Kettering.
Nick Kroll, Seth Meyers, Amy Schumer, John Mulaney, and special guests hosted the one-night-only event, taking the stage to outwit blood cancers and raising a record-breaking $2.3 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life.
The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.
Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients.
At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.